Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 60Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 39Head and Neck Neoplasms 26Gliosarcoma 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Central Nervous System Neoplasms 23Brain Neoplasms 22Rectal Neoplasms 21Breast Neoplasms 17Astrocytoma 17Sarcoma 16Neoplasms 16Glioma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Esophageal Neoplasms 14Carcinoma, Squamous Cell 11Lymphoma, Follicular 10Leukemia 10Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 7Myelodysplastic Syndromes 7Lymphoma, Mantle-Cell 7

Interventions

Radiotherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy × Radiotherapy × Clear all
NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
42 enrolled
Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡